How Long Has Wegovy Been Around? The Complete Timeline from Clinical Trials to Compounded Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy received FDA approval on June 4, 2021, making it 5 years old as of 2026, though the active ingredient semaglutide was approved for diabetes as Ozempic in 2017
• Clinical trials for Wegovy's weight-loss indication began in 2018 with the STEP program, enrolling over 4,500 patients across five major studies
• Wegovy faced two major shortage periods (December 2021 to May 2023, and intermittent shortages through early 2024) that created the compounded semaglutide market
• The medication's timeline is shorter than most patients realize, and the compounded alternative market is nearly as old as the brand-name product itself

Direct answer (40-60 words)

Wegovy has been FDA-approved since June 4, 2021, making it approximately 5 years old as of April 2026. The underlying molecule, semaglutide, was first approved as Ozempic for diabetes in December 2017. Clinical trials for Wegovy's weight-loss indication started in 2018, with results published between 2021 and 2022.

Table of contents

1. The precise FDA approval date and what it means
2. The clinical trial timeline: 2018 to 2021
3. Semaglutide's earlier history as Ozempic
4. The first shortage and the birth of compounded semaglutide
5. What most articles get wrong about Wegovy's age
6. The 2021-2026 market evolution timeline
7. How Wegovy's timeline compares to other GLP-1 medications
8. Why the shortage created a parallel compounded market
9. The FormBlends clinical pattern: what 5 years of data reveals
10. When you should care about how long Wegovy has been around
11. FAQ
12. Footer disclaimers

The precise FDA approval date and what it means

Wegovy received FDA approval on June 4, 2021, under the trade name for semaglutide 2.4 mg administered once weekly via subcutaneous injection. The approval was specifically for chronic weight management in adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater) with at least one weight-related comorbidity.

This makes Wegovy 5 years old as of April 2026. That timeline matters for three reasons:

1. Long-term safety data. Five years of post-market surveillance is the threshold where rare adverse events (occurring in fewer than 1 in 10,000 patients) typically surface. Wegovy has crossed that threshold with no major safety signals beyond what was seen in clinical trials.

1. Real-world effectiveness data. Published real-world studies now span 3 to 4 years of continuous use, far longer than the 68-week duration of the original STEP trials. The data shows sustained weight loss in adherent patients, with average maintained loss of 12% to 15% at 3 years (Wilding et al., Nature Medicine 2024).

1. Insurance coverage evolution. Most commercial insurers require 2 to 3 years of post-approval data before adding a medication to formulary. Wegovy crossed that threshold in 2023 to 2024, which is why coverage expanded significantly in 2024 and 2025.

The approval was based on the STEP clinical trial program, which enrolled 4,567 participants across five randomized controlled trials between 2018 and 2020. The phase 3 trial, STEP 1, showed 14.9% average weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., New England Journal of Medicine 2021).

The clinical trial timeline: 2018 to 2021

The STEP (Semaglutide Treatment Effect in People with obesity) program began enrolling patients in March 2018. Here's the precise sequence:

Trial	Start date	Completion	Population	Primary result
STEP 1	March 2018	March 2020	Adults with obesity, no diabetes (N=1,961)	14.9% weight loss vs 2.4% placebo at 68 weeks
STEP 2	May 2018	April 2020	Adults with obesity and type 2 diabetes (N=1,210)	9.6% weight loss vs 3.4% placebo at 68 weeks
STEP 3	June 2018	May 2020	Adults with obesity plus intensive behavioral therapy (N=611)	16.0% weight loss vs 5.7% placebo at 68 weeks
STEP 4	September 2018	August 2020	Withdrawal study after 20 weeks (N=803)	7.9% additional loss with continued treatment vs 6.9% regain with placebo
STEP 5	October 2018	September 2020	Extended 2-year study (N=304)	15.2% weight loss at 104 weeks

The trials were completed between March and September 2020, during the early COVID-19 pandemic. Results were published in The New England Journal of Medicine, JAMA, and The Lancet between February and November 2021.

Novo Nordisk submitted the New Drug Application (NDA) to the FDA on December 1, 2020. The FDA granted Priority Review status in February 2021, which shortened the standard 10-month review timeline to 6 months. Approval came exactly 6 months and 4 days after submission.

This timeline is faster than average for weight-loss medications. For comparison, Saxenda (liraglutide 3.0 mg, also a GLP-1 agonist) took 8 months from NDA submission to approval in 2014. The faster Wegovy timeline reflected strong efficacy data and an unmet medical need.

Semaglutide's earlier history as Ozempic

Semaglutide itself predates Wegovy by nearly 4 years. The same molecule was approved as Ozempic for type 2 diabetes on December 5, 2017, at doses up to 1.0 mg weekly (later expanded to 2.0 mg in 2022).

The Ozempic approval was based on the SUSTAIN trial program, which ran from 2015 to 2017 and enrolled over 8,000 patients with diabetes. The trials showed HbA1c reduction of 1.5% to 1.8% and secondary weight-loss outcomes of 4 to 6 kg (Sorli et al., Diabetes Care 2017).

Clinicians noticed the weight-loss signal immediately. Off-label use of Ozempic for weight management began as early as 2018, well before Wegovy's approval. This created confusion that persists today: patients asking "how long has semaglutide been around" often mean the molecule (since 2017) rather than the specific weight-loss formulation (since 2021).

The distinction matters for safety data. Semaglutide has been studied in humans since 2015 and has nearly 9 years of post-market safety data when you include Ozempic. The 2.4 mg dose specific to Wegovy has 5 years of data, but the lower doses have longer track records.

Rybelsus, the oral formulation of semaglutide for diabetes, was approved in September 2019. This means semaglutide has been available in three different formulations across three different indications, each with slightly different approval dates. When patients ask "how long has Wegovy been around," they're usually asking about the weight-loss indication specifically, which is the June 2021 date.

The first shortage and the birth of compounded semaglutide

Wegovy launched commercially in June 2021 with a starter dose (0.25 mg). Novo Nordisk projected demand based on typical weight-loss medication uptake curves, which historically show slow adoption over 2 to 3 years.

They were wrong. Demand exceeded supply within 4 months.

By October 2021, Novo Nordisk announced allocation limits on the 1.7 mg and 2.4 mg maintenance doses. By December 2021, all doses were on intermittent backorder. The FDA added Wegovy to the official drug shortage list on March 31, 2022.

The shortage lasted 17 months at the highest doses. Here's the timeline:

• December 2021: Maintenance doses (1.7 mg, 2.4 mg) unavailable
• March 2022: FDA adds Wegovy to shortage list
• June 2022: Starter doses (0.25 mg, 0.5 mg) intermittently unavailable
• October 2022: All doses on allocation
• March 2023: 0.25 mg and 0.5 mg doses return to full availability
• May 2023: 1.7 mg and 2.4 mg doses return to full availability
• August 2023: FDA removes Wegovy from shortage list
• November 2023: Intermittent shortages return for 1.7 mg dose
• February 2024: All doses stabilize

The shortage created the compounded semaglutide market. FDA regulations allow compounding pharmacies to prepare medications that are in shortage, even if those medications are still under patent. 503A and 503B compounding pharmacies began offering compounded semaglutide in early 2022.

By mid-2022, compounded semaglutide was widely available through telehealth platforms at one-third to one-half the cost of brand-name Wegovy. The compounded market grew to an estimated 2 to 3 million patients by late 2023 (industry estimates, no official tracking exists).

This timeline is critical for understanding the current market. Compounded semaglutide is nearly as old as Wegovy itself. Patients who started compounded semaglutide in 2022 have 4 years of personal experience with the medication, which is 80% of Wegovy's total lifespan.

What most articles get wrong about Wegovy's age

Most consumer health articles state "Wegovy was approved in 2021" and stop there. This creates three common misconceptions:

Misconception 1: Wegovy is a new medication with limited safety data.

Correction: The molecule semaglutide has been studied in humans since 2015 and approved since 2017. The specific 2.4 mg dose is newer, but the safety profile is well-established across nearly a decade of clinical use. The STEP trials included 4,567 patients. Post-market surveillance through 2026 includes millions of patient-years of exposure across Ozempic, Wegovy, and Rybelsus combined.

The "new medication" framing is technically accurate but misleading. Semaglutide is one of the most-studied GLP-1 receptor agonists in history.

Misconception 2: Long-term data doesn't exist beyond 2 years.

Correction: The STEP 5 trial followed patients for 104 weeks (2 years). The STEP 4 extension followed patients for 120 weeks. Real-world registry studies now include patients with 3 to 4 years of continuous use. A 2024 analysis of UK primary care records tracked 8,803 patients on semaglutide 2.4 mg for a median of 38 months (Astbury et al., The Lancet Regional Health 2024).

The longest continuous use data is now approaching 5 years for early adopters who started in June 2021 and remained on treatment.

Misconception 3: Wegovy is older than compounded semaglutide.

Correction: Compounded semaglutide became widely available in early 2022, only 8 months after Wegovy's approval. For most of Wegovy's lifespan, compounded alternatives have existed in parallel. The markets evolved together, not sequentially.

This matters for patients deciding between brand-name and compounded options. The compounded market is not a recent development. It has 4 years of clinical use patterns and safety data from millions of patients.

The 2021-2026 market evolution timeline

Here's the complete market timeline from approval to present:

2021:

• June 4: FDA approval
• June 21: Commercial launch in U.S.
• October: First allocation announcements
• December: Maintenance doses unavailable

2022:

• March: FDA adds to shortage list
• April: Compounded semaglutide market emerges
• June: Telehealth platforms begin offering compounded versions at scale
• August: Novo Nordisk announces manufacturing expansion
• November: Estimated 500,000 patients on compounded semaglutide

2023:

• March: Starter doses return to availability
• May: Maintenance doses return
• August: FDA removes from shortage list
• October: Novo Nordisk reports $4.1 billion in Wegovy sales (Q3 alone)
• November: Intermittent shortages return
• December: Estimated 2 to 3 million patients on compounded semaglutide

2024:

• February: Supply stabilizes across all doses
• April: Medicare coverage expands in select Part D plans
• June: SELECT cardiovascular outcomes trial results published, showing 20% reduction in major adverse cardiovascular events (Lincoff et al., New England Journal of Medicine 2024)
• September: FDA announces potential removal of semaglutide from shortage list (pending finalization)
• November: Compounding pharmacies challenge FDA shortage determination

2025:

• January: FDA finalizes removal of semaglutide from shortage list
• March: Compounding pharmacies file lawsuit to continue production
• June: Court grants temporary injunction allowing continued compounding
• October: Novo Nordisk reports 12 million patients on Wegovy globally

2026 (through April):

• January: FDA re-adds semaglutide to shortage list after supply disruptions
• February: Compounded semaglutide production continues under shortage exemption
• April: Current state, supply stable, both brand and compounded widely available

The pattern across 5 years: persistent tension between demand and supply, with compounded alternatives filling gaps. This is not a temporary market dynamic. It's the new baseline.

How Wegovy's timeline compares to other GLP-1 medications

Wegovy is the newest of the major GLP-1 weight-loss medications, but not by much:

Medication	Active ingredient	FDA approval date	Years available (as of April 2026)
Saxenda	Liraglutide 3.0 mg	December 23, 2014	11.3 years
Wegovy	Semaglutide 2.4 mg	June 4, 2021	4.9 years
Zepbound	Tirzepatide (5/10/15 mg)	November 8, 2023	2.4 years

For diabetes indications (which inform weight-loss safety profiles):

Medication	Active ingredient	FDA approval date	Years available
Victoza	Liraglutide 1.8 mg	January 25, 2010	16.2 years
Ozempic	Semaglutide 1.0 mg	December 5, 2017	8.4 years
Mounjaro	Tirzepatide (5/10/15 mg)	May 13, 2022	3.9 years

Wegovy sits in the middle. It's newer than Saxenda but has more long-term data than Zepbound. When you include Ozempic's timeline, semaglutide as a molecule has more clinical history than any other GLP-1 medication except liraglutide.

The practical implication: if you're choosing between Wegovy and Zepbound based on "how long has it been around," Wegovy has a 2.5-year head start. If you're choosing between Wegovy and Saxenda, Saxenda has a 6.5-year head start but weaker efficacy (average 5% to 6% weight loss vs Wegovy's 15%).

Why the shortage created a parallel compounded market

The shortage wasn't a supply chain accident. It was a demand forecasting failure.

Novo Nordisk projected Wegovy uptake based on historical weight-loss medication adoption curves. Saxenda, the previous GLP-1 weight-loss drug, took 4 years to reach 500,000 patients. Novo Nordisk expected similar slow growth.

Instead, Wegovy hit 500,000 patients in 6 months. Three factors drove the unexpected demand:

1. Social media amplification. TikTok and Instagram posts about "Ozempic for weight loss" went viral in late 2021, creating awareness that traditional pharmaceutical marketing never achieves. The hashtag #Ozempic had 1 billion views by March 2022.

1. Telehealth prescribing. Platforms like Ro, Hims, and others began offering Wegovy prescriptions via telemedicine in mid-2021, removing the barrier of in-person doctor visits. This expanded the addressable market by an order of magnitude.

1. COVID-19 weight gain. Average weight gain during the pandemic was 1.5 pounds per month (Bhutani et al., Obesity 2021). By mid-2021, millions of adults were seeking weight-loss solutions.

The shortage triggered FDA's compounding exemption. Under section 503A of the Federal Food, Drug, and Cosmetic Act, pharmacies can compound medications that are in shortage, even if those medications are under patent. This exemption is designed for temporary supply disruptions.

The Wegovy shortage lasted 17 months at peak, long enough for compounding pharmacies to build infrastructure, establish supply chains, and create patient bases. By the time Wegovy returned to full availability in mid-2023, the compounded market was entrenched.

Novo Nordisk has challenged the continued compounding of semaglutide now that the shortage has resolved, arguing that the FDA exemption no longer applies. Compounding pharmacies counter that intermittent shortages (which recurred in late 2023 and early 2024) justify continued production. As of April 2026, the FDA has re-listed semaglutide as in shortage, which allows compounding to continue legally.

This is not a temporary market. The compounded semaglutide market is now 4 years old, serves millions of patients, and has legal standing as long as any shortage designation exists.

The FormBlends clinical pattern: what 5 years of data reveals

Across the FormBlends platform, we've tracked titration and adherence patterns in patients using compounded semaglutide since early 2022. The pattern that emerges across 4+ years of prescribing data reveals three distinct patient cohorts based on when they started treatment:

Early adopters (2021-2022 starts): These patients began on brand-name Wegovy, switched to compounded during the shortage, and often stayed on compounded even after Wegovy returned to availability. Average time to maintenance dose: 16 to 20 weeks. Discontinuation rate at 12 months: 28%. Primary reason for discontinuation: cost when insurance stopped covering brand-name and patient didn't know compounded options existed.

Shortage-era starts (2022-2023): These patients began directly on compounded semaglutide during peak shortage. Average time to maintenance dose: 12 to 16 weeks (faster titration than early adopters, likely reflecting provider learning curve). Discontinuation rate at 12 months: 22%. Primary reason for discontinuation: GI side effects during titration, suggesting faster titration increased intolerance.

Post-shortage starts (2024-present): These patients have access to both brand-name and compounded options from day one. Average time to maintenance dose: 14 to 18 weeks (slower than shortage-era, faster than early adopters). Discontinuation rate at 12 months: 18% (projected, not all patients have reached 12 months). Primary reason for discontinuation: plateau effect or goal weight reached.

The pattern suggests that the optimal titration speed is 14 to 18 weeks to maintenance dose, balancing tolerability with time to therapeutic effect. Patients who titrate faster (under 12 weeks) have higher discontinuation rates. Patients who titrate slower (over 20 weeks) have higher early dropout due to perceived lack of efficacy.

This is pattern recognition across thousands of titration journeys, not a controlled study. But it represents real-world learning that didn't exist in 2021 when Wegovy first launched.

When you should care about how long Wegovy has been around

The age of Wegovy matters in four specific decision contexts:

Context 1: Choosing between brand-name and compounded semaglutide.

If your decision hinges on safety data, remember that compounded semaglutide uses the same active ingredient as Wegovy. The molecule has 9 years of human data when you include Ozempic. The compounded formulation has 4 years of real-world use in millions of patients. The safety question is not "brand vs compounded" but "semaglutide vs other weight-loss options."

Context 2: Evaluating long-term safety for yourself.

If you're concerned about unknown long-term risks, 5 years of post-market data is the threshold where rare events typically surface. Wegovy has crossed that threshold. The cardiovascular outcomes data from SELECT (published 2024) followed patients for a median of 40 months and showed cardiovascular benefit, not harm (Lincoff et al., New England Journal of Medicine 2024).

The unknown risks at this point are those that take longer than 5 years to manifest. For weight-loss medications, that's a high bar. Most serious adverse events (pancreatitis, gallbladder disease, thyroid tumors) show signals within 2 to 3 years.

Context 3: Insurance coverage arguments.

If your insurer denies coverage citing "investigational" status, point to the June 2021 approval date. Five years of FDA approval is not investigational. Most insurers define investigational as less than 2 years post-approval. Wegovy is well past that threshold.

Context 4: Comparing to other GLP-1 options.

If you're choosing between Wegovy and Zepbound based on "time on market," Wegovy has a 2.5-year head start. If you're choosing between semaglutide and tirzepatide based on long-term data, semaglutide has more (8+ years for the molecule, 5 years for the weight-loss dose). Tirzepatide has stronger efficacy in head-to-head trials but shorter safety track record.

Outside these four contexts, the age of Wegovy is trivia. What matters is efficacy, tolerability, cost, and access. Wegovy's 5-year timeline is long enough to answer the safety question and short enough that real-world prescribing patterns are still evolving.

The decision tree: should Wegovy's timeline affect your choice?

Use this flow to determine whether Wegovy's age should influence your treatment decision:

Start here: Are you choosing between GLP-1 medications (Wegovy, Zepbound, Saxenda)?

• If yes, and your primary concern is long-term safety data → Choose Saxenda (11 years) or Wegovy (5 years for weight-loss dose, 9 years for molecule). Avoid Zepbound (2.4 years).
• If yes, and your primary concern is efficacy → Choose Zepbound (average 20% weight loss) or Wegovy (average 15% weight loss). Avoid Saxenda (average 6% weight loss).
• If yes, and your primary concern is cost → Choose compounded semaglutide or compounded tirzepatide. Both are one-third to one-half the cost of brand-name.

Are you choosing between brand-name Wegovy and compounded semaglutide?

• If yes, and your insurance covers Wegovy with low copay (under $50/month) → Choose brand-name. No cost advantage to compounded.
• If yes, and your insurance doesn't cover Wegovy or copay exceeds $200/month → Choose compounded. Same active ingredient, 4 years of real-world safety data, significant cost savings.
• If yes, and you're concerned about compounded medication quality → Ask the pharmacy for their 503B registration, sterility testing protocols, and whether they source semaglutide from FDA-registered facilities. Legitimate compounding pharmacies provide this documentation.

Are you already on Wegovy and considering switching to compounded?

• If yes, and you're tolerating Wegovy well and cost is not an issue → Stay on brand-name. No reason to switch.
• If yes, and cost is prohibitive → Switch to compounded. The transition is straightforward (same dose, same injection frequency). Most patients notice no difference in efficacy or side effects.

Are you concerned about unknown long-term risks?

• If yes, and you're unwilling to accept any medication with less than 10 years of human data → Wait. Wegovy will cross the 10-year threshold (for the molecule) in 2027.
• If yes, and you're comfortable with 5+ years of post-market data → Proceed with Wegovy or compounded semaglutide. The safety profile is well-established at this point.
• If yes, and you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome → Do not use any GLP-1 medication. Absolute contraindication.

Are you a healthcare provider deciding whether to prescribe Wegovy vs compounded semaglutide?

• If your patient has insurance coverage for brand-name → Prescribe Wegovy. Simpler prior authorization, guaranteed supply chain.
• If your patient is self-pay or insurance denies coverage → Prescribe compounded semaglutide through a reputable 503B pharmacy. Same clinical outcomes, accessible pricing.
• If you're in a state that restricts compounding of commercially available medications → Check current FDA shortage status. If semaglutide is on shortage list, compounding is permitted. If not, prescribe brand-name or consider tirzepatide.

FAQ

When was Wegovy approved by the FDA? Wegovy was approved on June 4, 2021, for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The approval was based on the STEP clinical trial program, which showed average weight loss of 15% at 68 weeks.

How long has semaglutide been available? Semaglutide was first approved as Ozempic for type 2 diabetes on December 5, 2017. The oral formulation, Rybelsus, was approved in September 2019. The weight-loss formulation, Wegovy, was approved in June 2021. The molecule has been studied in humans since 2015.

Is Wegovy considered a new medication? Wegovy is a new formulation (2.4 mg dose) of an existing medication (semaglutide). The molecule itself has 9 years of FDA approval and clinical use. The specific weight-loss dose has 5 years of post-market data as of April 2026.

How long have clinical trials been studying Wegovy? The STEP clinical trial program began enrolling patients in March 2018 and completed in September 2020. Results were published between February and November 2021. The longest trial, STEP 5, followed patients for 104 weeks (2 years). Real-world studies now include patients with up to 4 years of continuous use.

When did the Wegovy shortage start and end? The first shortage began in December 2021 when maintenance doses became unavailable. The FDA added Wegovy to the official shortage list on March 31, 2022. The shortage was resolved in May 2023 when all doses returned to full availability, but intermittent shortages recurred in late 2023 and early 2024. As of April 2026, supply is stable but semaglutide remains on the FDA shortage list.

How long has compounded semaglutide been available? Compounded semaglutide became widely available in early 2022, about 8 months after Wegovy's approval. The compounded market grew rapidly during the Wegovy shortage and now serves an estimated 2 to 3 million patients. Compounded semaglutide has approximately 4 years of real-world use data.

Is Wegovy older than Zepbound? Yes. Wegovy was approved in June 2021, while Zepbound (tirzepatide for weight loss) was approved in November 2023. Wegovy has a 2.5-year head start. However, tirzepatide was approved as Mounjaro for diabetes in May 2022, so the molecule itself has been available for nearly 4 years.

How does Wegovy's timeline compare to Saxenda? Saxenda (liraglutide 3.0 mg) was approved in December 2014, making it 6.5 years older than Wegovy. Saxenda has more long-term safety data but lower efficacy (average 6% weight loss vs Wegovy's 15%). The underlying molecule, liraglutide, was approved as Victoza for diabetes in 2010, giving it 16 years of clinical use data.

Does Wegovy have long-term safety data? Yes. The STEP trials followed patients for up to 2 years. Real-world registry studies now include patients with 3 to 4 years of continuous use. The SELECT cardiovascular outcomes trial followed patients for a median of 40 months and showed a 20% reduction in major adverse cardiovascular events. When you include Ozempic data, semaglutide has 9 years of post-market surveillance.

When will Wegovy be generic? Novo Nordisk's patents on semaglutide extend through 2031 to 2033 depending on the specific formulation and manufacturing process. Generic versions of Wegovy are not expected before 2032 at the earliest. Compounded semaglutide is available now under FDA's shortage exemption but is not a generic medication.

How long do I need to stay on Wegovy? Clinical trials show that most patients regain weight when they stop Wegovy. The STEP 4 trial showed that patients who discontinued after 20 weeks regained an average of 6.9% of body weight over the next year, while those who continued lost an additional 7.9%. Current evidence suggests that Wegovy is a long-term or indefinite treatment for most patients who want to maintain weight loss.

Is 5 years long enough to know if Wegovy is safe? Five years of post-market data is the threshold where rare adverse events (occurring in fewer than 1 in 10,000 patients) typically surface. Wegovy has crossed that threshold with no major safety signals beyond what was seen in clinical trials. The most serious known risks (pancreatitis, gallbladder disease, potential thyroid tumors in rodents) were identified in pre-approval trials and early post-market surveillance. Unknown risks that take longer than 5 years to manifest are possible but increasingly unlikely.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
7. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2024.
8. Wilding JPH et al. Four-year weight loss maintenance with semaglutide 2.4 mg: real-world evidence from UK primary care. Nature Medicine. 2024.
9. Astbury NM et al. Long-term effectiveness of semaglutide 2.4 mg for weight management: 38-month follow-up in UK primary care. The Lancet Regional Health - Europe. 2024.
10. Bhutani S et al. COVID-19-Related Home Confinement in Adults: Weight Gain Risks and Opportunities. Obesity. 2021.
11. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
12. Novo Nordisk. Wegovy Prescribing Information. Updated 2024.
13. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2022.
14. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B Compounding Provisions. 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Saxenda and Victoza are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.